{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T19:52:57Z","timestamp":1649015577302},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2000,2]]},"DOI":"10.1007\/s11864-000-0014-0","type":"journal-article","created":{"date-parts":[[2007,7,26]],"date-time":"2007-07-26T08:52:11Z","timestamp":1185439931000},"page":"43-50","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous T-cell lymphoma\/leukemia"],"prefix":"10.1007","volume":"1","author":[{"given":"Richard S.","family":"Siegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"14_CR1","unstructured":"Kuzel TM, Guitart J, Rosen ST: Cutaneous T-cell Lymphomas. In Hematology: Basic Principles and Practice. Edited by Hoffman R, Benz Jr. EJ, Shattil SJ, et al. 1372\u20131387. A thorough summary of CTCL."},{"issue":"suppl 2","key":"14_CR2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000246981","volume":"189","author":"R Willemze","year":"1994","unstructured":"Willemze R, Beljaards RC, Meijer CJ, et al.: Classification of primary cutaneous lymphomas. Historical overview and perspectives. Dermatology 1994, 189(suppl 2):8\u201315. Excellent discussion of CTCL classification.","journal-title":"Dermatology"},{"key":"14_CR3","first-page":"354","volume":"90","author":"R Willemze","year":"1997","unstructured":"Willemze R, Kerl H, Sterry W, et al.: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997, 90:354\u2013371.","journal-title":"Blood"},{"key":"14_CR4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","volume":"260","author":"MA Weinstock","year":"1988","unstructured":"Weinstock MA, Horm JW: Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988, 260:42\u201346.","journal-title":"JAMA"},{"key":"14_CR5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0889-8588(18)30054-6","volume":"9","author":"AH Rook","year":"1995","unstructured":"Rook AH, Heald P: The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:997\u20131010. A thorough summary of immunopathogenesis of CTCL.","journal-title":"Hematol Oncol Clin North Am"},{"key":"14_CR6","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/1097-0142(19881015)62:8<1658::AID-CNCR2820620834>3.0.CO;2-J","volume":"62","author":"MA Weinstock","year":"1988","unstructured":"Weinstock MA, Horm JW: Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides. Cancer 1988, 62:1658\u20131661.","journal-title":"Cancer"},{"key":"14_CR7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","volume":"321","author":"FJ Kaye","year":"1989","unstructured":"Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989, 321:1784\u20131790.","journal-title":"N Engl J Med"},{"key":"14_CR8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","volume":"33","author":"JJ Herrmann","year":"1995","unstructured":"Herrmann JJ, Roenigk HH, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995, 33:234\u2013242. Good review of PUVA.","journal-title":"J Am Acad Dermatol"},{"key":"14_CR9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","volume":"9","author":"GW Jones","year":"1995","unstructured":"Jones GW, Hoppe RT, Glatstein E: Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1057\u20131076. Good review of TSEBT.","journal-title":"Hematol Oncol Clin North Am"},{"key":"14_CR10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00000421-199204000-00005","volume":"15","author":"S Reddy","year":"1992","unstructured":"Reddy S, Parker CM, Shidnia H, et al.: Total skin electron beam radiation therapy for mycosis fungoides. Am J Clin Oncol 1992, 15:119\u2013124.","journal-title":"Am J Clin Oncol"},{"key":"14_CR11","first-page":"691","volume":"63","author":"RT Hoppe","year":"1979","unstructured":"Hoppe RT, Cox RS, Fuks Z, et al.: Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979, 63:691\u2013700.","journal-title":"Cancer Treat Rep"},{"key":"14_CR12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0360-3016(97)00127-2","volume":"38","author":"PA Quiros","year":"1997","unstructured":"Quiros PA, Ones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen\/ ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 1997, 38:1027\u20131035.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"14_CR13","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","volume":"5","author":"RT Hoppe","year":"1987","unstructured":"Hoppe RT, Abel EA, Deneau DG, et al.: Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol 1987, 5:1796\u20131803.","journal-title":"J Clin Oncol"},{"key":"14_CR14","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","volume":"19","author":"DL Ramsay","year":"1988","unstructured":"Ramsay DL, Ed M, Halperin PS, et al.: Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988, 19:684\u2013691.","journal-title":"J Am Acad Dermatol"},{"key":"14_CR15","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(19831215)52:12<2214::AID-CNCR2820521207>3.0.CO;2-H","volume":"52","author":"NM Price","year":"1983","unstructured":"Price NM, Hoppe RT, Deneau DG: Ointment-based mechlorethamine treatment for mycosis fungoides. Cancer 1983, 52:2214\u20132219.","journal-title":"Cancer"},{"key":"14_CR16","first-page":"202","volume":"13","author":"HS Zackheim","year":"1994","unstructured":"Zackheim HS: Topical carmustine (BCNU) for patch\/ plaque mycosis fungoides. Semin Dermatol 1994, 13:202\u2013206.","journal-title":"Semin Dermatol"},{"key":"14_CR17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0889-8588(18)30061-3","volume":"9","author":"ST Rosen","year":"1995","unstructured":"Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the S\u00e9zary syndrome. Hematol Oncol Clin North Am 1995, 9:1109\u20131116.","journal-title":"Hematol Oncol Clin North Am"},{"key":"14_CR18","first-page":"310","volume":"7","author":"S Broder","year":"1980","unstructured":"Broder S, Bunn PA Jr: Cutaneous T-cell lymphomas. Semin Oncol 1980, 7:310\u2013331.","journal-title":"Semin Oncol"},{"key":"14_CR19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(89)70251-6","volume":"21","author":"HS Zackheim","year":"1989","unstructured":"Zackheim HS, Epstein EH: Low-dose methotrexate for the S\u00e9zary Syndrome. J Am Acad Dermatol 1989, 21:757\u2013762.","journal-title":"J Am Acad Dermatol"},{"key":"14_CR20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","volume":"87","author":"TM Kuzel","year":"1996","unstructured":"Kuzel TM, Hurria A, Samuelson E, et al.: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996, 87:906\u2013911.","journal-title":"Blood"},{"key":"14_CR21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V61.2.279.279","volume":"61","author":"MR Grever","year":"1983","unstructured":"Grever MR, Bisaccia E, Scarborough DA, et al.: An Investigation of 2\u2019-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983, 61:279\u2013282.","journal-title":"Blood"},{"key":"14_CR22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","volume":"9","author":"FJ Cummings","year":"1991","unstructured":"Cummings FJ, Kim K, Neiman RS, et al.: Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991, 9:565\u2013571.","journal-title":"J Clin Oncol"},{"key":"14_CR23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0190-9622(88)70224-8","volume":"19","author":"AP Dang-Vu","year":"1988","unstructured":"Dang-Vu AP, Olsen EA, Vollmer RT, et al.: Treatment of cutaneous T-cell lymphoma with 2\u2019-deoxycoformycin (pentostatin). J Am Acad Dermatol 1988, 19:692\u2013698.","journal-title":"J Am Acad Dermatol"},{"key":"14_CR24","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","volume":"57","author":"PA Bunn","year":"1986","unstructured":"Bunn PA, Ihde DC, Foon KA: The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986, 57:1689\u20131695.","journal-title":"Cancer"},{"key":"14_CR25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","volume":"20","author":"EA Olsen","year":"1989","unstructured":"Olsen EA, Rosen ST, Vollmer RT, et al.: Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989, 20:395\u2013407.","journal-title":"J Am Acad Dermatol"},{"key":"14_CR26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","volume":"9","author":"EA Olsen","year":"1995","unstructured":"Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1089\u20131107.","journal-title":"Hematol Oncol Clin North Am"},{"key":"14_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","volume":"13","author":"TM Kuzel","year":"1995","unstructured":"Kuzel TM, Roenigk HH, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the S\u00e9zary syndrome. J Clin Oncol 1995, 13:257\u2013263.","journal-title":"J Clin Oncol"},{"key":"14_CR28","first-page":"3578","volume":"92","author":"R Stadler","year":"1998","unstructured":"Stadler R, Otte HG, Luger T, et al.: Prospective randomized multicenter clinical trial on the use of interferon a-2a plus acitretin versus interferon a-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998, 92:3578\u20133581.","journal-title":"Blood"},{"issue":"suppl 1","key":"14_CR29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0959-8049(96)00327-9","volume":"33","author":"J Nichols","year":"1997","unstructured":"Nichols J, Foss F, Kuzel TM, et al.: Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997, 33(suppl 1):34\u201336.","journal-title":"Eur J Cancer"},{"key":"14_CR30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(98)70403-7","volume":"39","author":"MN Saleh","year":"1998","unstructured":"Saleh MN, LeMaistre CF, Kuzel TM, et al.: Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998, 39:63\u201373. Report of recently approved DAB389IL-2.","journal-title":"J Am Acad Dermatol"},{"key":"14_CR31","doi-asserted-by":"crossref","unstructured":"Kuzel T, Olsen E, Martin A, et al.: Pivotal phase III trial of two dose levels of DAB389IL-2 (Ontak) for the treatment of mycosis fungoides. ASH 1997, Abstract #2607.","DOI":"10.1016\/S0923-1811(98)84232-1"},{"key":"14_CR32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","volume":"316","author":"R Edelson","year":"1987","unstructured":"Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987, 316:297\u2013303.","journal-title":"N Engl J Med"},{"key":"14_CR33","first-page":"1","volume":"25","author":"R Edelson","year":"1991","unstructured":"Edelson R, Heald, Perez, et al.: Photopheresis update. Prog Dermatol 1991, 25:1\u20136.","journal-title":"Prog Dermatol"},{"key":"14_CR34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archderm.134.8.1001","volume":"134","author":"E Fraser-Andrews","year":"1998","unstructured":"Fraser-Andrews E, Seed P, Whittaker S, et al.: Extracorporeal photopheresis in S\u00e9zary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998, 134:1001\u20131005.","journal-title":"Arch Dermatol"},{"key":"14_CR35","unstructured":"Hymes K, Duvic M, Heald P, et al.: Oral bexarotene benefits patients with refractory advanced stage CTCL. ASH 1999, Abstract #425."},{"key":"14_CR36","unstructured":"Siegel RS, Martone B, Guitart J, et al.: Phase II trial of ALL-trans retinoic acid (ATRA) in the treatment of relapsed\/refractory mycosis fungoides\/S\u00e9zary syndrome (MF\/SS). ASH 1999, Abstract #423."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-000-0014-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0014-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T10:42:53Z","timestamp":1587811373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-000-0014-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["14"],"URL":"https:\/\/doi.org\/10.1007\/s11864-000-0014-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}